Advance Programme

ADVANCE PROGRAMME (PDF)

Wednesday, 09 November 2011

14h30-16h00 SO 01 TREATMENT OF ALCOHOLISM
14.30-14.55 SO 0101 Which target- prevention of relapse
in abstinence or reduction of alcohol intake?
TBC
14.55-15.20 SO 0102 Alcohol dependence and depression
Julia Sinclair (UK)
15.20-15.45 SO 0103 A potential new treatment for alcohol
dependency
Hannu Alho (Finland)
15.45-16.00 Discussion
16h00-16h30 Coffee break
16.30-18.00 SO 02 DEPRESSION AND ANXIETY:
TREATING THE DIFFICULT PATIENT

SO 0201 The shy and anxious
Daniel Meron (United Kingdom)

SO 0202 The poor responder
Hamish McAllister-Williams (United Kingdom)

Background
Case study with voting
Treatment approaches

Symposium sponsored by an unrestricted
educational grant from H. Lundbeck A/S

18.00-19.00 Opening reception

Thursday, 10 November 2011

09h00-10h30 SO 03 ADVANCES IN TREATMENT OF MDD AND GAD
09.00-09.25 SO 0301 Depression in schizophrenia
Istvan Bitter (Hungary)
09.25-09.50 SO 0302 Risk Benefit of atypicals in GAD
Borwin Bandelow (Germany)
09.50-10.15 SO 0303 Atypicals as treatment in MDD
– advantages and risks
Hans-Jürgen Möller (Germany)
10.15-10.30 Discussion
10h30-11h00 Coffee break
11h00-12h30 SO 04 WHY ARE THERE SO FEW NEW
PSYCHOTROPICS?
11.00-11.25 SO 0401 Has the demand for evidence in psychiatry become counterproductive?
Elias Eriksson (Sweden)
11.25-11.50 SO 0402 Economic barriers to developing new treatments
Anders Gersel Pedersen (Denmark)
11.50-12.15 SO 0403 Sunset on new psychotropics
Stuart Montgomery (UK)
12.15-12.30 Discussion
12h30-13h30 Lunch
13.30-15.00 SO 05 ADVANCES IN THE THERAPY
OF TREATMENT RESISTANCE
13.30-13.55 SO 0501 Is personalised gene targeted therapy
in resistant depression possible?
Alessandro Serretti (Italy)
13.55-14.20 SO 0502 Advances in the theraphy of treatment resistance
David Baldwin (UK)
14.20-14.45 SO 0503 Modern treatment of resistant depression
Daniel Souery (Belgium)
14.45-15.00 Discussion
15.00-16.00 SO 06 DEBATE: THE AMINE HYPOTHESIS IS A DEAD END FOR DRUG DEVELOPMENT

Pro: Timothy Dinan (Ireland)
Contra: Mike Briley (France)
16h00-16h30 Coffee break
16.30-18.00 SO 07 MULTIDIMENSIONAL INTERACTIONS IN DEPRESSIONS
16.30-16.55 SO 0701 The challenges posed by ethnic diversity in the
treatment of depressed patients
Driss Moussaoui (Morocco)
16.55-17.20 SO 0702 Drug interactions in polymedicated depressed patients
Sheldon Preskorn (USA)
17.20-17.45 SO 0703 The clinical importance of monoamine interactions in antidepressant therapy
Pierre Blier (Canada)
17.45-18.00 Discussion

Symposium sponsored by an unrestricted educational grant from Pierre Fabre Medicaments

Friday, 11 November 2011

09h00-10h30 SO 08 TREATMENT OF RESISTANT
DISORDERS
09.00-09.25 SO 0801 Antidepressant-resistance in unipolar
and bipolar depression
Zoltán Rihmer (Hungary)
09.25-09.50 SO 0802 Treatment of resistant OCD
Naomi Fineberg (UK)
09.50-10.15 SO 0803 Prevention of PTSD – does a window
of opportunity exist?
Joseph Zohar (Israel)
10.15-10.30 Discussion
10h30-11h00 Coffee break
11h00-12h30 SO 09 ADVANCES WITH HERBAL REMEDIES
11.00-11.25
SO 0901 Is lavender an anxiolytic?
Siegfried Kasper (Austria)
11.25-11.50
SO 0902 Who benefits from St Johns Wort in depression
Markus Gastpar (Germany)
11.50-12.15 SO 0903 Gingko extract in dementia
Ralf Ihl (Germany)
12.15-12.30 Discussion
Symposium sponsored by an unrestricted educational
grant from Dr. Willmar Schwabe GmbH & Co. KG.
12h30-13h30 Lunch
13h30-15h500 SO 10 HOT TOPICS
13.30-13.55 SO 1001 Recent advances in the pharmacological
treatment of sleep disorders
Tom Roth (USA)
13.55-14.20 SO 1002 Is treatment of adolescent depression different from adult
Brigitte Reichart (Germany)
14.20-14.45 SO 1003 Bringing the placebo response under control
Gary Sachs (USA)
14.45-15.00 Discussion
15.00-16.30 SO 11 DILEMMAS IN BIPOLAR DISORDER
15.00-15.25 SO 1101 Evidence for treatment of bipolar spectrum Giulio Perugi (Italy)
15.25-15.50 SO 1102 Epidemiological evidence for a bipolar spectrum
beyond BP1 and 2
Jules Angst (Switerland)
15.50-16.15 SO 1103 When is depression bipolar? : implications for treatment
Alan Young (UK)
16h00-16h30 Coffee break